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Abstract 
Pyrazinamide (PZA) is one of the mainstays WHO-recommended drugs for therapy of tuberculosis (TB). The emergence of PZA 
resistance in clinical isolates of M. tuberculosis is often associated with pncA gene mutations encoding PZase. A local clinical 
isolate of  Mycobacterium tuberculosis strain showed phenotipe resistant to PZA at concentration of 10 Pg/mL. The ORF of pncA 
gene of the isolate showed deletion of guanine base at position 81, then followed by shortening of 70 amino acids from C-
terminal of PZAse which has 186 amino acid residues. The mutant of PZase took frame shift of amino acids after the residue at 
position 27. The pncA gene mutation at the level of genotype, that produced a physical-chemical alteration of the active site or 
the metal-binding site of PZase, in this case perturbing or lossing its activity was proposed as trigering the PZA resistance in P14 
clinical isolate of M. tuberculosis strain. 
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Nomenclature 
TB        Tuberculosis 
PZA        Pyrazinamide 
MDR         Multidrug-resistant  
PZase        Pyrazinamidase  
 
1. Introduction 
Tuberculosis (TB) is a bacterial infectious disease, caused by Mycobacterium tuberculosis. Currently, TB has 
been the seventh most common cause of death  in the world. Indonesia has been clasified as a "high burden country" 
for tuberculosis, cited in the highest fifth rank of the 22 countries related to high burden. There are about 500,000 
new cases of TB annually and 175,000 of them are deaths in Indonesia1,11. Of the TB cases in Indonesia, about 2 
percent of new cases and 12 percent of the recurring cases are the multidrug-resistant (MDR) strain1,11.  
Pyrazinamide (PZA) is a potential drug that is commonly used to threat active tuberculosis (TB), along with 
other drugs during the initial phase of therapy (generally the first two months of treatment). The PZA has a 
spesifically antibacterial merit only to resist against Mycobacterium tuberculosis and M. africanum2,8. 
PZA is adsorpted by M. tuberculosis by passive diffusion, then converted to be active form by pyrazinamidase 
(PZase) enzyme that is encoded by pncA gene, to resist against dormant or semidormant microorganisms although 
the role of PZA against intracellular organisms remains uncertain4,8,10. In one study, pyrazinoic acid remained 
outside of M. tuberculosis cells at a neutral or alkaline pH but accumulated within cells at an acidic pH5,6. In the 
same study, M. smegmatis which is resistant to PZA, and was found converting PZA to pyrazinoic acid via an active 
efflux mechanism, did not accumulate the metabolite at an acidic pH. Other mycobacterial strains exhibited to be 
resistant to PZA, due to lack of PZase activity or absence of transport mechanisms to take up the drug3,6.  
PZA resistance in M. tuberculosis is commonly associated with mutations in the pncA gene encoding 
pyrazinamidase (PZase)7,13. Mutation of pncA in mycobacterial isolates is unique from each different geographical 
region7,10,11. Determination of pncA mutation is needed to make genetic marker. The paper reported a novel mutation 
in pncA gene of a PZA-resistant M. tuberculosis  from local isolate (P14) which linked to its protein model as a basis 
of the emergence of PZA resistance in the isolate. 
 
2. Methods 
2.1. Bacteria and plasmid 
An isolate of PZA-resistant M. tuberculosis (P14) and a PZA-sensitive isolate named as H37Rv strain were 
obtained from Health Research Center, Bandung, Indonesia.  
 
2.2.  Mycobacterium tuberculosis growth condition 
M. tuberculosis was grown in a solid medium, named as Lowenstein-Jensen (LJ) at 37ºC for 2 weeks until single 
colony was found. The LJ medium is composed of egg suspension 60% (v/v) ; malachite green 1% (w/v); glycerol 
0.8% (v/v); KH2PO4 0.2% (w/v); MgSO4.7H20 0.02% (w/v); and  citrate magnesium 0.04% (w/v)10,11.  
 
2.3.  Chromosomal DNA isolation  
The chromosomal DNA of M. tuberculosis was isolated by alkali lyses method using wizard genomic DNA 
purification kit (Promega). The pellet cells were suspended in 480 Pl 50 mM EDTA, then added with 120 Pl 
lysozyme and incubated at 37ºC for 1 hour. The mixture was centrifuged for 2 minutes at 13.000g to separate the 
pellet cells from their supernatant. The cell pellet was added by Nuclei lysis Solution and Protein Precipitation 
solution solvent, incubated for 5 minutes at 80°C, then cooled in room temperature. After it was centrifuged for 3 
minutes, it was followed by isopropanol additon to obtain DNA precipitate. DNA precipitate formed was then 
washed by ethanol 70% (v/v), after it was centrifuged for 2 minutes. Etanol was thrown; DNA pellet was dissolved 
in Rehydration Solution DNA solvent  to use DNA amplification10. 
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2.4. DNA Amplification  
 
The amplification of a full length of pncA gene was performed by using pncAF and pncAR primers that have 
sequences: 5’-GAG CAT ATG CGG GCG TTG ATC ATC-’3; and 5’-GAA GAT CTG GAG CTG CAA ACC AAC 
TC –’3 respectively. The primers were constructed having nucleotides adapter for an NdeI restriction sites in pncAF 
and BglII restriction sites in pncAR. The restriction nucleotides are marked by italic fonts. The reaction mixture for 
PCR was created in 25 ȝL volume which consists of 2.5 pmol of each primer, 50 ng of template DNA, 1.25 unit of 
Fast DNA Polymerase KAPA2G enzyme, 1x PCR buffer (20 mM Tris-Cl, pH 8.4, 50 mM KCl), and 0,2 mM 
dNTPs. PCR process was run by DNA-thermal Cycler machine, consisting of an initial 10 minutes denaturation and 
enzyme activation at 94°C followed by 25 cycles of 94°C denaturation for 1 minute, 54°C 1 minute,  and 72°C 
elongation for 2 minutes and a final 7 minutes elongation. The PCR products were analyzed in agarose gel 
electrophoresis and purified by GFX purification kit (Amersham, New Jersey, USA). 
2.5. DNA sequencing and analysis 
 
Automated DNA sequencing was performed by dideoxy-Sanger method at First BASE Laboratories Sdn Bhd,  
Selangor, Malaysia. The pncA gene was sequenced with the primers, pncAF and pncR. Sequence analyses were 
conducted with DNA Star Software using programs of SeqManTMII for DNA sequence and MegAlignTM for the 
amino acid sequence (Lasergene, Biocomputing software for windows; DNASTAR, Inc., Madison, USA, 1997). All 
sequencing processes included the PZA-susceptible strain M. tuberculosis H37Rv (ATCC 27294) as a wild-type 
control. Each sequence was compared with that in the control strain and the appropriate published sequence. 
 
2.6. Modeling of the three-dimensional structure of PZase 
 
A model of the PZase mutant of M. tuberculosis clinical isolate was constructed by SWISS-MODEL on the 
basis of the known three-dimensional structure of PZase from PZA-sensitive M. tuberculosis H37Rv, which has a 
number access “3PL1.pdb” at Protein Data Bank. The model structures of mutant PZase were visualized in PyMOL 
1.310. 
 
3. Results and Discussion 
Pirazinamidase that was encoded by pncA gene is one enzyme that plays an important role in the appearance of 
PZA sensitivity in M. tuberculosis. Clinical trials and genetic studies confirm the relationship between the loss of 
activity of PZA resistance pirazinamidase. It shows that clinical isolates of M. PZA -resistant tuberculosis rarely 
have total deletion of pncA3,6,10. It is stated that in addition to the loss of activity pirazinamidase, there are other 
mechanisms involved in the appearance of PZA resistance among clinical isolates of M. tuberculosis. PZA 
resistance in clinical isolates of M. tuberculosis has been associated with point mutations, insertions, deletions in the 
gene pncA. Generally, each geographic area has a distinctive type of pncA mutations, resulting in the identification 
of mutations in the pncA for PZA-resistant of Mycobacterium from locally clinical isolates which were required to 
construct the genetic marker 10,11.  
 
3.1 Amplification of pncA gene from PZA resistant and sensitive M. tuberculosis 
Amplification of pncA gene was carried out by PCR tecnique using chromosomal DNA of PZA resistant and 
sensitive M. tuberculosis as template DNA. The amplification process has been carried out using the Fast DNA 
Polymerase KAPA2G enzyme. The use of this enzyme is designed to get more time PCR efficiency and also to 
avoid the occurrence of mutation in vitro for the pncA gene during amplification process. This enzyme has activity 
of 5'o3' polymerase and 5'o3' exonuclease, and capable of amplifying the DNA fragment as 5 kb. In addition, this 
enzyme has a quite low reading error, which is 1 error for 1.7 x 105 nucleotide per cycle. Accoding to this case, it is 
possible to amplify the pncA gene (0.6 kb) by using the enzyme.  
The coding region of pncA gene that resides in the locus of Rv2043c from nucleotides 2288681 to 2289241 was 
amplified by using pncAF and pncAR primers. The primers were designed directly from the sequences of pncA gene 
of PZA sensitive M. tuberculosis (H37Rv) listed in the genbank with ID number: 888260. By using the primers, the 
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PCR proses generated a DNA fragment at 0.6 kb in agarose gel electrophoresis (Fig. 1). The PCR- produced DNA 
fragments have showed a similiar size to the pncA of M. tuberculosis H37Rv in GenBank, which is 561 bp.  
 
 
 
Fig. 1. Electroforegram of PCR product. The 0.6 kb corressponds to pncA gene size. Lane 1, 100 bp DNA marker leader; lane 2, negative control; 
lane 3, the PCR product using  genomic DNA template from PZA-sensitive M. tuberculosis (H37Rv); lanes 4-8, the PCR products using genomic 
DNA template from PZA-resistant M. tuberculosis (P14) 
 
3.2. PncA nucleotide sequence of M. tuberculosis PZA-resistant and sensitive 
The sequencing was done using two primers according to the design in Fig. 2. Combination of these two primary 
types can determine the nucleotide 580, in which there is pncA nucleotide sequence. 
 
 
 
Fig. 2. The pncA nucleotide sequence determination scheme 
 
The corresponding 0.6 fragment was completely sequenced. The sequencing was done using two primers  
according to the design in Fig. 2. To determine the presence of mutations in the pncA gene of PZA -resistant 
Mycobacterium analyzed comparing with PZA-sensitive strain, the alignment analysis of nucleotides was done. The 
nucleotide sequence analysis of the 0.6 fragment of H37Rv, strain from PZA sensitive M. tuberculosis  showed 
similarity 100% with pncA of Genbank. However, the pncA nucleotide sequence alignment of clinical isolates of 
PZA-resistant M. tuberculosis isolates (P14) which is compared to the pncA of PZA sensitive M. tuberculosis 
(H37Rv) and GenBank indicates a guanine deletion at position 81 (Fig. 3). The  pncA mutation in the P14 clinical 
isolate is classified as a new mutation, that has not been previously reported.  
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Fig . 3. Nucleotide alignment analysis of pncA from PZA-resistant M. tuberculosis (P14) toward  pncA from PZA-sensistif M. tuberculosis 
(H37Rv) and GenBank. Nucleotide mutation is marked with red oval. The pncA of P14 isolate had deletion G at position 81.   
 
Silico translation of pncA gene of H37RV and P14 isolates produced 186 and 116 amino acids respectively (Fig. 
4). The mutant of PZase took frame shift of amino acids after the residue at position 27, then stopped after the 
residue at position 116. The PZase of P14 isolate got shortening of 70 amino acids from its C-terminal (Fig. 4).  
 
 
Fig . 4. Silico translation product of pncA gene. The pncA of PZA-sensitive M. tuberculosis (H37Rv) resulted 186 amino acids (A), but there 
were only 116 amino acids for PZA-resistant M. tuberculosis (P14) (B). The precise bases of pncA gene from H37Rv and P14 strains are marked 
by underline.   
 
3.3. Three-dimentional-structure model for the mutant Pzase 
To determine the effect of amino acid deletion in the P14 PZase structure, a structural modeling study has been 
carried out. The P14 PZase exhibited 14.5% similar amino acid sequences to the wild-type PZase (Fig. 5). However, 
the mutant structure of P14 PZase amended many interactions in its wild-type  structure, expecially in the regions 
that contain the catalytic residues of PZAse. It has been reported that PZase contains some catalytic residues, 
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including Asp8, Lys96, Ala134 and Cys138 in the active site, and Asp49, His51 and His71 in the metal-binding 
site8,9,11. It is suggested that producing a physical-chemical alteration of the active site or the metal-binding site, in 
this case, perturbs or loses its activity and trigers the PZA resistance.  
 
 
Fig. 5. Alignment Structure of  mutant PZase  toward  its wild type. Blue for mutant, and grey for wild type PZase 
4. Conclusion 
Mutation of pncA gene in P14 clinical isolate that produced a physical-chemical alteration of the active site or 
the metal-binding site of PZase, causing perturbing or lossing its activity was proposed as trigering the PZA 
resistance.  
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